Weekly Omnicell, Inc. (NASDAQ:OMCL) Ratings as of May 17, 2018

May 17, 2018 - By Nellie Rakes

Omnicell, Inc. (NASDAQ:OMCL) Corporate Logo
Big Money Sentiment increased to 1.12 in Q4 2017. It has change of 0.10, from 2017Q3’s 1.02. The ratio improved due to Omnicell, Inc. positioning: 14 sold and 72 reduced. 27 funds amassed stakes and 69 increased stakes. Investors holded 37.10 million in 2017Q3 but now own 37.38 million shares or 0.77% more.
Moreover, Prudential Fincl has 0% invested in Omnicell, Inc. (NASDAQ:OMCL) for 63,055 shs. 20 were accumulated by Hanseatic Mgmt. Voya Management Lc holds 0.03% in Omnicell, Inc. (NASDAQ:OMCL) or 336,677 shs. Tradewinds Capital Mngmt Limited Liability Company has 307 shs for 0.01% of their capital. The Michigan-based Solutions Ltd Company has invested 0% in Omnicell, Inc. (NASDAQ:OMCL). Conestoga Cap Advsrs Limited Com invested in 3.34% or 1.79M shs. Grisanti Cap Mgmt Lc holds 1,200 shs or 0.02% of its capital. Rockefeller Fincl reported 469,672 shs. Miles holds 0.15% in Omnicell, Inc. (NASDAQ:OMCL) or 5,512 shs. Dimensional Fund Advisors L P holds 0.03% in Omnicell, Inc. (NASDAQ:OMCL) or 1.52 million shs. State Street Corporation accumulated 1.11M shs. Stephens Invest Grp Inc Ltd Co has invested 0.47% in Omnicell, Inc. (NASDAQ:OMCL). Moreover, Millennium Mngmt Limited has 0% invested in Omnicell, Inc. (NASDAQ:OMCL). Regions Fin Corporation has invested 0% in Omnicell, Inc. (NASDAQ:OMCL). Brinker Cap reported 0.01% stake.

Omnicell, Inc. had 7 insider sales and 0 buys since December 15, 2017. This’s net activity of $1.81 million. Shares for $99,559 were sold by Kuipers Peter J. on Friday, December 15. 8,186 shs were sold by LIPPS RANDALL A, worth $361,938. JOHNSTON DAN S also sold $507,248 worth of Omnicell, Inc. (NASDAQ:OMCL) on Monday, April 16. PETERSMEYER GARY S also sold $25,544 worth of Omnicell, Inc. (NASDAQ:OMCL) shs.

Omnicell, Inc. (NASDAQ:OMCL) Ratings Coverage

In total 4 analysts cover Omnicell (NASDAQ:OMCL). “Buy” rating has 2, “Sell” are 0, while 2 are “Hold”. 50% are bullish. 7 are the (NASDAQ:OMCL)’s analyst reports since December 5, 2017 according to StockzIntelligence Inc. The stock rating was downgraded by Craig Hallum to “Hold” on Friday, February 2. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Tuesday, December 5. On Tuesday, December 5 the stock has “Buy” rating by Oppenheimer. On Thursday, February 1 the firm has “Buy” rating by Cantor Fitzgerald given. On Thursday, April 26 Cantor Fitzgerald maintained the shares of OMCL in report with “Buy” rating. On Monday, January 29 the rating was maintained by Oppenheimer with “Buy”. On Friday, February 2 the rating was maintained by PiperJaffray with “Neutral”. Listed here are Omnicell, Inc. (NASDAQ:OMCL) PTs and latest ratings.

26/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $63.0000 Maintain
02/02/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Neutral Old Target: $38 New Target: $44 Maintain
02/02/2018 Broker: Craig Hallum Rating: Hold Downgrade
01/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $63.0 Maintain
29/01/2018 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain
05/12/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $60.0 Maintain
05/12/2017 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain

OMCL is reaching $46.35 during the last trading session, after increased 0.65%.Omnicell, Inc. has volume of 224,857 shares. Since May 17, 2017 OMCL has risen 5.20% and is uptrending. The stock underperformed the S&P500 by 6.35%.

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide.The firm is worth $1.80 billion. The firm operates through two divisions, Automation and Analytics, and Medication Adherence.87.45 is the P/E ratio. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Savvy Mobile Medication Workstation, which provides a platform for hospital information systems.

Another two news for Omnicell, Inc. (NASDAQ:OMCL) were briefly published by: Seekingalpha.com on April 27, 2018 with title “Omnicell’s (OMCL) CEO Randall Lipps on Q1 2018 Results – Earnings Call Transcript”. The other Prnewswire.com‘s article was titled “Omnicell Announces First Quarter 2018 Results” and published on April 26, 2018.

Omnicell, Inc. (NASDAQ:OMCL) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.